Literature DB >> 23508966

Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis.

Sayaka Maeda1, Takanori Matsui, Masayoshi Takeuchi, Sho-ichi Yamagishi.   

Abstract

BACKGROUND: Ninety percent of glucose filtered by the glomerulus is reabsorbed by a sodium-glucose cotransporter 2 (SGLT2), which is expressed mainly on the apical membrane of renal proximal tubules. Because blockade of SGLT2 promotes urinary glucose excretion and thereby improves hyperglycaemia, selective inhibition of SGLT2 has been proposed as a potential therapeutic target for the treatment of patients with diabetes. Moreover, advanced glycation end products (AGEs)-receptor (RAGE) system induces apoptosis of tubular cells, thereby playing a role in diabetic nephropathy as well. However, the pathophysiological crosstalk of SGLT2 with AGEs-RAGE axis and its role in diabetic nephropathy remains unknown.
METHODS: This study investigated whether and how blockade of SGLT2 could prevent AGEs-elicited apoptosis of high glucose-exposed proximal tubular cells in vitro.
RESULTS: SGLT2 was expressed in tubular cells. Tubular SGLT2 expression and glucose entry into the cells were completely blocked by the treatment with small interfering RNAs (siRNAs) raised against SGLT2. High glucose increased reactive oxygen species generation and RAGE expression levels in tubular cells, both of which were partly suppressed by SGLT2 siRNAs or an antioxidant, N-acetylcysteine. Further, high glucose was found to augment the AGEs-induced tubular cell apoptosis, which was also inhibited by SGLT2 siRNAs.
CONCLUSIONS: Our present data suggest that SGLT2-mediated, high glucose-induced reactive oxygen species generation could augment the AGEs-induced apoptotic cell death of tubular cells via RAGE induction. SGLT2 may play some role in tubular apoptosis in diabetic nephropathy.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  AGEs; RAGE; ROS; SGLT2; diabetic nephropathy

Mesh:

Substances:

Year:  2013        PMID: 23508966     DOI: 10.1002/dmrr.2407

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  26 in total

1.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

Review 2.  Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.

Authors:  Milton Packer
Journal:  J Am Soc Nephrol       Date:  2020-04-10       Impact factor: 10.121

Review 3.  A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.

Authors:  Martin C Michel; Eric Mayoux; Volker Vallon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-26       Impact factor: 3.000

4.  Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.

Authors:  Ryousuke Satou; Michael W Cypress; T Cooper Woods; Akemi Katsurada; Courtney M Dugas; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-04

Review 5.  Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

Authors:  Sandeep K Mallipattu; Jaime Uribarri
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

Review 6.  Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.

Authors:  Bancha Satirapoj
Journal:  Kidney Dis (Basel)       Date:  2017-04-08

7.  Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation.

Authors:  Nobutaka Nakamura; Takanori Matsui; Yuji Ishibashi; Sho-Ichi Yamagishi
Journal:  Diabetol Metab Syndr       Date:  2015-05-24       Impact factor: 3.320

Review 8.  Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.

Authors:  Sanjay Kalra; Vikram Singh; Dinesh Nagrale
Journal:  Adv Ther       Date:  2016-07-16       Impact factor: 3.845

Review 9.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727

10.  Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study.

Authors:  Diana Nabrdalik-Leśniak; Katarzyna Nabrdalik; Katarzyna Sedlaczek; Patryk Główczyński; Hanna Kwiendacz; Tomasz Sawczyn; Weronika Hajzler; Karolina Drożdż; Mirela Hendel; Krzysztof Irlik; Paweł Stelmach; Piotr Adamczyk; Andrzej Paradysz; Sławomir Kasperczyk; Tomasz Stompór; Janusz Gumprecht
Journal:  Oxid Med Cell Longev       Date:  2021-07-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.